151 related articles for article (PubMed ID: 35951740)
1. Brimonidine tartrate ophthalmic solution 0.025% for redness relief: an overview of safety and efficacy.
Lee JS; Kim CY
Expert Rev Clin Pharmacol; 2022 Aug; 15(8):911-919. PubMed ID: 35951740
[TBL] [Abstract][Full Text] [Related]
2. Brimonidine Ophthalmic Solution 0.025% for Reduction of Ocular Redness: A Randomized Clinical Trial.
McLaurin E; Cavet ME; Gomes PJ; Ciolino JB
Optom Vis Sci; 2018 Mar; 95(3):264-271. PubMed ID: 29461408
[TBL] [Abstract][Full Text] [Related]
3. Low-dose brimonidine for relief of ocular redness: integrated analysis of four clinical trials.
Ackerman SL; Torkildsen GL; McLaurin E; Vittitow JL
Clin Exp Optom; 2019 Mar; 102(2):131-139. PubMed ID: 30525235
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of Efficacy and Safety of Brimonidine Tartrate Ophthalmic Solution, 0.025% for Treatment of Ocular Redness.
Torkildsen GL; Sanfilippo CM; DeCory HH; Gomes PJ
Curr Eye Res; 2018 Jan; 43(1):43-51. PubMed ID: 29120262
[TBL] [Abstract][Full Text] [Related]
5. Improvement of objective ocular redness measured with Keratograph 5M in glaucoma patients after instilling brimonidine drops.
Montolío-Marzo E; Fernández-Narros R; Morales-Fernández L; García-Bella J; Sáenz-Francés F; García-Feijoo J; Martínez-de-la-Casa JM
Eur J Ophthalmol; 2024 Mar; 34(2):480-486. PubMed ID: 37661653
[TBL] [Abstract][Full Text] [Related]
6. Twelve-month results of an ongoing randomized trial comparing brimonidine tartrate 0.2% and timolol 0.5% given twice daily in patients with glaucoma or ocular hypertension. Brimonidine Study Group 2.
LeBlanc RP
Ophthalmology; 1998 Oct; 105(10):1960-7. PubMed ID: 9787370
[TBL] [Abstract][Full Text] [Related]
7. Demographic and clinical factors associated with development of brimonidine tartrate 0.2%-induced ocular allergy.
Manni G; Centofanti M; Sacchetti M; Oddone F; Bonini S; Parravano M; Bucci MG
J Glaucoma; 2004 Apr; 13(2):163-7. PubMed ID: 15097264
[TBL] [Abstract][Full Text] [Related]
8. Clinical experience with brimonidine 0.2% and timolol 0.5% in glaucoma and ocular hypertension.
Schuman JS
Surv Ophthalmol; 1996 Nov; 41 Suppl 1():S27-37. PubMed ID: 8970247
[TBL] [Abstract][Full Text] [Related]
9. Brimonidine gel 0.33% rapidly improves patient-reported outcomes by controlling facial erythema of rosacea: a randomized, double-blind, vehicle-controlled study.
Layton AM; Schaller M; Homey B; Hofmann MA; Bewley AP; Lehmann P; Nohlgård C; Sarwer DB; Kerrouche N; Ma YM
J Eur Acad Dermatol Venereol; 2015 Dec; 29(12):2405-10. PubMed ID: 26416154
[TBL] [Abstract][Full Text] [Related]
10. Effects of systemic beta-blocker therapy on the efficacy and safety of topical brimonidine and timolol. Brimonidine Study Groups 1 and 2.
Schuman JS
Ophthalmology; 2000 Jun; 107(6):1171-7. PubMed ID: 10857839
[TBL] [Abstract][Full Text] [Related]
11. Over-the-Counter Ocular Decongestants in the United States - Mechanisms of Action and Clinical Utility for Management of Ocular Redness.
Hosten LO; Snyder C
Clin Optom (Auckl); 2020; 12():95-105. PubMed ID: 32801982
[TBL] [Abstract][Full Text] [Related]
12. Development and use of brimonidine in treating acute and chronic elevations of intraocular pressure: a review of safety, efficacy, dose response, and dosing studies.
Walters TR
Surv Ophthalmol; 1996 Nov; 41 Suppl 1():S19-26. PubMed ID: 8970246
[TBL] [Abstract][Full Text] [Related]
13. OTC brimonidine (Lumify) for ocular redness.
Med Lett Drugs Ther; 2018 Oct; 60(1558):176. PubMed ID: 30335046
[No Abstract] [Full Text] [Related]
14. A 1-year study of brimonidine twice daily in glaucoma and ocular hypertension. A controlled, randomized, multicenter clinical trial. Chronic Brimonidine Study Group.
Schuman JS; Horwitz B; Choplin NT; David R; Albracht D; Chen K
Arch Ophthalmol; 1997 Jul; 115(7):847-52. PubMed ID: 9230823
[TBL] [Abstract][Full Text] [Related]
15. A 3-month comparison of efficacy and safety of brimonidine-purite 0.15% and brimonidine 0.2% in patients with glaucoma or ocular hypertension.
Mundorf T; Williams R; Whitcup S; Felix C; Batoosingh A
J Ocul Pharmacol Ther; 2003 Feb; 19(1):37-44. PubMed ID: 12648302
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of once-daily topical brimonidine tartrate gel 0.5% for the treatment of moderate to severe facial erythema of rosacea: results of two randomized, double-blind, and vehicle-controlled pivotal studies.
Fowler J; Jackson M; Moore A; Jarratt M; Jones T; Meadows K; Steinhoff M; Rudisill D; Leoni M
J Drugs Dermatol; 2013 Jun; 12(6):650-6. PubMed ID: 23839181
[TBL] [Abstract][Full Text] [Related]
17. The Results of Preoperative Use of Topical Brimonidine in Strabismus Surgery.
Ucar F; Cetinkaya S
J Ocul Pharmacol Ther; 2021 May; 37(4):230-235. PubMed ID: 33684337
[No Abstract] [Full Text] [Related]
18. The evolving pharmacotherapeutic profile of brimonidine, an alpha 2-adrenergic agonist, after four years of continuous use.
Cantor LB
Expert Opin Pharmacother; 2000 May; 1(4):815-34. PubMed ID: 11249518
[TBL] [Abstract][Full Text] [Related]
19. Difference in vasoconstrictors: oxymetazoline vs. brimonidine.
Okwundu N; Cline A; Feldman SR
J Dermatolog Treat; 2021 Mar; 32(2):137-143. PubMed ID: 31294643
[TBL] [Abstract][Full Text] [Related]
20. Reversible cicatricial ectropion precipitated by topical brimonidine eye drops.
Aristodemou P; Baer R
Ophthalmic Plast Reconstr Surg; 2008; 24(1):57-8. PubMed ID: 18209648
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
